Technology
A UNIQUE INTRACELLULAR DRUG DELIVERY TECHNOLOGY…
Enabling technologies that target the intracellular undruggable space are becoming a key priority for the pharma industry.
PEP-Therapy has developed a unique, clinically-validated, technology for intracellular drug delivery of various cargos, with unique features:
- Rapid and efficient intracellular drug delivery
- Clinically validated
- Excellent safety profile and high stability
- Improved bioavailability through effective endosomal escape
- Targeted delivery to cytoplasmic or nuclear compartments
- Mastered GMP chemical synthesis
PEP-Therapy holds a patented portfolio of Cell Penetrating Peptides (CPPs), comprising:
- 4 cytoplasm-targeting shuttles
- 2 nuclear-targeting shuttles
… TO UNLOCK A NEW PIPELINE OF PROMISING INTRACELLULAR DRUG CANDIDATES
Our technology enhances intracellular delivery of multiple payloads, such as:
- Peptides, proteins
- Antibodies with intracellular targeting (to extend their use beyond extracellular proteins targeting), bispecific antibodies, ADCs, nanobodies
- Nucleic acids: gene therapy, ASO, siRNA, genome editing tools
CASEs STUDies
INTRACELLULAR PEPTIDE DELIVERY
PEP-Therapy’s flagship anticancer product, PEP-010, currently advancing trough Phase Ib clinical trial, combines:
- An optimized CPP,
- An active peptide as a cargo
The structure allows:
- Rapid and direct cell translocation
- Endosomal trapping escape
- High drug efficacy and safety
INTRACELLULAR ANTIBODY DELIVERY
Our optimized CPP combined with an anti-CEACAM5 antibody (Ab) demonstrated:
- Efficient intracellular delivery of Ab with unmatched efficiency, surpassing existing CPPs
- Specific targeting of colorectal cancer cells
- Endosomal escape
Such targeting allows for:
- Minimizing toxicity
- Avoiding unspecific cellular uptake
- Using lower doses while boosting efficacy
